Ardsley Advisory Partners LP Astrazeneca PLC Transaction History

Ardsley Advisory Partners LP

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$53.02 - $135.75 $3.5 Million - $8.96 Million	-66,000 Reduced 39.76%	100,000 $5.48 Million
Q2 2022 Aug 15, 2022	SELL	$59.26 - $71.14 $888,900 - $1.07 Million	-15,000 Reduced 8.29%	166,000 $11 Million
Q1 2022 May 16, 2022	BUY	$55.72 - $67.12 $10 Million - $12.1 Million	180,350 Added 27746.15%	181,000 $12 Million
Q4 2021 Feb 14, 2022	SELL	$54.02 - $63.83 $16.2 Million - $19.2 Million	-300,050 Reduced 99.78%	650 $38,000
Q3 2021 Nov 15, 2021	BUY	$55.56 - $60.79 $8.37 Million - $9.16 Million	150,700 Added 100.47%	300,700 $18.1 Million
Q2 2021 Aug 16, 2021	BUY	$48.42 - $60.18 $7.26 Million - $9.03 Million	150,000 New	150,000 $8.99 Million
Q4 2020 Feb 16, 2021	SELL	$48.52 - $58.02 $460,940 - $551,190	-9,500 Closed	0 $0
Q3 2020 Nov 13, 2020	SELL	$53.07 - $61.1 $265,350 - $305,500	-5,000 Reduced 34.48%	9,500 $521,000
Q2 2020 Aug 14, 2020	BUY	$43.1 - $55.31 $624,950 - $801,995	14,500 New	14,500 $767,000
Q1 2020 May 15, 2020	SELL	$37.79 - $51.33 $283,425 - $384,975	-7,500 Closed	0 $0
Q4 2019 Feb 14, 2020	BUY	$42.46 - $50.46 $318,450 - $378,450	7,500 New	7,500 $374,000

1,361

475M

5.39M

3.75M

Ticker AZN
Exchange OTC
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 3,099,020,032
Market Cap $200B
Description
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, By...

Get notified when there are updates to the investment portfolio of Ardsley Advisory Partners LP, based on Form 13F filings with the SEC.

Stay updated on Ardsley Advisory Partners LP with notifications on news.